Merck's Phase 3 Lung Cancer Study of Keytruda-Lynparza Combo Misses Main Endpoints
By Colin Kellaher
Merck & Co. on Thursday reported the failure of a late-stage study of a combination of Keytruda and Lynparza in the early treatment of certain lung cancer patients.
The Rahway, N.J., drugmaker said the Phase 3 study of Keytruda in combination with maintenance Lynparza missed the dual primary endpoints of overall survival and survival without the disease getting worse as an initial treatment for certain patients with metastatic nonsquamous non-small cell lung cancer.
The company jointly develops and commercializes Lynparza with AstraZeneca.
Merck said the safety profiles of the two drugs were consistent with those observed in prior studies, adding that it is continuing a full evaluation of the study data, and that it is committed to exploring Keytruda-based combinations and novel candidates in lung cancer.
Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 21, 2024 07:30 ET (11:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending